Shares of Soleno Therapeutics are up 190% or $8.75 in pre-market trading at $13.53 after the company disclosed positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR Extended-Release tablets for the treatment of Prader-Willi syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
- Soleno Therapeutics price target raised to $14 from $8 at Oppenheimer
- Soleno Therapeutics appoints Matthew Pauls to board of directors
- Soleno Therapeutics reports Q2 EPS (81c), consensus (83c)
- SLNO Upcoming Earnings Report: What to Expect?